Logo
x

Search

Subscribe Now

Argenx

argenx and Zai Lab Report the NMPA’s Approval of Vyvgart Hytrulo for Chronic Inflammatory Demyelinating Polyneuropathy

argenx and Zai Lab Report the NMPA’s Approval of Vyvgart Hytrulo for Chronic Inflammatory Demyelinating Polyneuropathy

  • November 12, 2024
argenx’ Vyvgart Hytrulo Bags the US FDA’s Approval for Treating Chronic Inflammatory Demyelinating Polyneuropathy

argenx’ Vyvgart Hytrulo Bags the US FDA’s Approval for Treating Chronic Inflammatory Demyelinating Polyneuropathy

  • June 25, 2024
argenx Reports the US FDA’s Acceptance of sBLA for Vyvgart Hytrulo with Priority Review for Chronic Inflammatory Demyelinating Polyneuropathy (CIDP)

argenx Reports the US FDA’s Acceptance of sBLA for Vyvgart Hytrulo with Priority Review for Chronic Inflammatory Demyelinating Pol...

  • February 20, 2024
argenx’s Vyvdura Injection Receives MHLW’s Approval for Generalized Myasthenia Gravis

argenx’s Vyvdura Injection Receives MHLW’s Approval for Generalized Myasthenia Gravis

  • January 18, 2024
Insights+: EMA Marketing Authorization of New Drugs in November 2023

Insights+: EMA Marketing Authorization of New Drugs in November 2023

  • December 29, 2023
Argenx Reports Results of VYVGART Hytrulo in P-III study for Primary Immune Thrombocytopenia

Argenx Reports Results of VYVGART Hytrulo in P-III study for Primary Immune Thrombocytopenia

  • November 28, 2023
Image

Incisive News in 3 Shots.

Contact Us

Our Information

Follow Us

Copyright © 2024 PharmaShots - All Rights Reserved.